论文部分内容阅读
目的:观察“通利大肠”对慢性阻塞性肺疾病(COPD)模型大鼠肺组织P物质(SP)、血管活性肠肽(VIP)含量的影响,从神经肽角度探讨COPD“从肠论治”的效应机制。方法:采用熏烟联合气管注射脂多糖复制COPD大鼠模型。50只雄性大Wistar鼠随机分为正常组、模型组、治肠组、治肺组、肺肠同治组。正常组和模型组均灌胃给予生理盐水,治肠组、治肺组、肺肠同治组分别用治肠药(生大黄)、治肺药(生石膏、苦杏仁、瓜蒌皮)、肺肠同治药(生大黄、生石膏、苦杏仁、瓜蒌皮)灌胃,连续7 d。用免疫组织化学法和酶联免疫吸附法检测肺组织中SP、VIP含量。结果:免疫组化结果显示,与正常组相比,模型组大鼠肺组织SP表达较强,而治肠组、治肺组、肺肠同治组表达较弱;VIP在正常大鼠支气管上皮表达较强,模型组表达明显减弱,各治疗组VIP表达明显增强。酶联免疫吸附法结果显示,与正常组相比,SP在模型组肺组织中含量明显升高,VIP含量明显降低(P<0.01);与模型组相比,治肠组、治肺组、肺肠同治组肺组织SP含量均明显降低,VIP含量明显升高(P<0.01或P<0.05);与治肺组相比,肺肠同治组肺组织SP含量明显降低(P<0.05)。结论:通利大肠或治肺基础上增加通利大肠,可调节COPD模型大鼠肺组织神经肽SP、VIP的含量,这可能是COPD“从肠论治”的效应机制之一。
OBJECTIVE: To observe the effect of Tom Lee on the content of substance P (SP) and vasoactive intestinal peptide (VIP) in the lung tissue of chronic obstructive pulmonary disease (COPD) model rats and to explore the relationship between COPD Intestine governance "effect mechanism. Methods: COPD rats were induced by injecting lipopolysaccharide with fumigation and intratracheal tracheal injection. Fifty male Wistar rats were randomly divided into normal group, model group, treatment of intestine group, treatment of lung group, lung intestine. Normal group and model group were given intragastric administration of saline, treatment group, treatment of lung group, lung intestine were treated with intestinal medicine (rhubarb), lung medicine (gypsum, bitter almond, melon skin), lung intestine Tongzhi medicine (rhubarb, gypsum, bitter almonds, melon skin) for 7 days. The contents of SP and VIP in lung tissue were detected by immunohistochemistry and enzyme-linked immunosorbent assay. Results: Immunohistochemical results showed that compared with the normal group, the expression of SP in the lung tissue of the model group was stronger than that in the normal group, while the expression of SP in the colon, lung and pancreas groups was weaker. VIP expression in the normal rat bronchial epithelium The expression of VIP in the model group was obviously weakened, and the VIP expression in each treatment group was significantly enhanced. The results of enzyme-linked immunosorbent assay showed that compared with the normal group, the content of SP in the model group was significantly increased and the content of VIP was significantly decreased (P <0.01). Compared with the model group, The content of SP in the lung tissue of lung and intestine was significantly decreased and the content of VIP was significantly increased (P <0.01 or P <0.05). Compared with the lung-treated group, the content of SP in the lung of the intestine was significantly decreased (P <0.05). CONCLUSION: The increase of Tongli intestine on the basis of Tongli’s large intestine or the treatment of lung can regulate the content of neuropeptide SP and VIP in the lung tissue of COPD model rats, which may be one of the effector mechanisms of COPD.